Logo image of DCPH

DECIPHERA PHARMACEUTICALS IN (DCPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DCPH - US24344T1016 - Common Stock

25.59 USD
+0.02 (+0.08%)
Last: 6/10/2024, 8:00:00 PM
25.61 USD
+0.02 (+0.08%)
After Hours: 6/10/2024, 8:00:00 PM
Fundamental Rating

4

Taking everything into account, DCPH scores 4 out of 10 in our fundamental rating. DCPH was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DCPH as it has an excellent financial health rating, but there are worries on the profitability. DCPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DCPH had negative earnings in the past year.
DCPH had a negative operating cash flow in the past year.
In the past 5 years DCPH always reported negative net income.
DCPH had a negative operating cash flow in each of the past 5 years.
DCPH Yearly Net Income VS EBIT VS OCF VS FCFDCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

DCPH has a Return On Assets of -45.24%. This is comparable to the rest of the industry: DCPH outperforms 52.53% of its industry peers.
Looking at the Return On Equity, with a value of -60.25%, DCPH is in line with its industry, outperforming 58.99% of the companies in the same industry.
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROIC N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
DCPH Yearly ROA, ROE, ROICDCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

With an excellent Gross Margin value of 96.95%, DCPH belongs to the best of the industry, outperforming 97.91% of the companies in the same industry.
DCPH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for DCPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
DCPH Yearly Profit, Operating, Gross MarginsDCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

DCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
DCPH has more shares outstanding than it did 1 year ago.
DCPH has more shares outstanding than it did 5 years ago.
DCPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DCPH Yearly Shares OutstandingDCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DCPH Yearly Total Debt VS Total AssetsDCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 7.32 indicates that DCPH is not in any danger for bankruptcy at the moment.
DCPH has a better Altman-Z score (7.32) than 83.07% of its industry peers.
There is no outstanding debt for DCPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACC8.89%
DCPH Yearly LT Debt VS Equity VS FCFDCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

DCPH has a Current Ratio of 4.19. This indicates that DCPH is financially healthy and has no problem in meeting its short term obligations.
DCPH has a Current ratio (4.19) which is comparable to the rest of the industry.
A Quick Ratio of 3.94 indicates that DCPH has no problem at all paying its short term obligations.
DCPH's Quick ratio of 3.94 is in line compared to the rest of the industry. DCPH outperforms 44.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 3.94
DCPH Yearly Current Assets VS Current LiabilitesDCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

DCPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.96%.
DCPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.51%.
Measured over the past years, DCPH shows a very strong growth in Revenue. The Revenue has been growing by 57.16% on average per year.
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%

3.2 Future

DCPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.21% yearly.
DCPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.42% yearly.
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DCPH Yearly Revenue VS EstimatesDCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
DCPH Yearly EPS VS EstimatesDCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DCPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DCPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCPH Price Earnings VS Forward Price EarningsDCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCPH Per share dataDCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as DCPH's earnings are expected to grow with 20.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y20.37%

More info and screens

0

5. Dividend

5.1 Amount

DCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DECIPHERA PHARMACEUTICALS IN

NASDAQ:DCPH (6/10/2024, 8:00:00 PM)

After market: 25.61 +0.02 (+0.08%)

25.59

+0.02 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2024-05-10/bmo
Earnings (Next)08-07 2024-08-07/bmo
Inst Owners6.97%
Inst Owner Change0%
Ins Owners26.79%
Ins Owner Change0%
Market Cap2.21B
Revenue(TTM)174.91M
Net Income(TTM)-190.42M
Analysts71.25
Price Target27.25 (6.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.41%
Min EPS beat(2)8.03%
Max EPS beat(2)8.79%
EPS beat(4)4
Avg EPS beat(4)8.32%
Min EPS beat(4)6.6%
Max EPS beat(4)9.87%
EPS beat(8)7
Avg EPS beat(8)5.71%
EPS beat(12)8
Avg EPS beat(12)3.61%
EPS beat(16)12
Avg EPS beat(16)5.04%
Revenue beat(2)1
Avg Revenue beat(2)-3.37%
Min Revenue beat(2)-9.86%
Max Revenue beat(2)3.11%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-9.86%
Max Revenue beat(4)7.77%
Revenue beat(8)5
Avg Revenue beat(8)0.97%
Revenue beat(12)8
Avg Revenue beat(12)1.76%
Revenue beat(16)12
Avg Revenue beat(16)51.69%
PT rev (1m)1.26%
PT rev (3m)17.06%
EPS NQ rev (1m)9.43%
EPS NQ rev (3m)8.94%
EPS NY rev (1m)1.43%
EPS NY rev (3m)3.18%
Revenue NQ rev (1m)2.15%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)0.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.65
P/FCF N/A
P/OCF N/A
P/B 7
P/tB 7
EV/EBITDA N/A
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS2.02
BVpS3.65
TBVpS3.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.95%
FCFM N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.04%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 3.94
Altman-Z 7.32
F-Score4
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)87.89%
Cap/Depr(5y)217.78%
Cap/Sales(3y)2.44%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%
EBIT growth 1Y-9.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.52%
EBIT Next 3Y4.87%
EBIT Next 5YN/A
FCF growth 1Y33.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.37%
OCF growth 3YN/A
OCF growth 5YN/A

DECIPHERA PHARMACEUTICALS IN / DCPH FAQ

What is the fundamental rating for DCPH stock?

ChartMill assigns a fundamental rating of 4 / 10 to DCPH.


What is the valuation status for DCPH stock?

ChartMill assigns a valuation rating of 1 / 10 to DECIPHERA PHARMACEUTICALS IN (DCPH). This can be considered as Overvalued.


What is the profitability of DCPH stock?

DECIPHERA PHARMACEUTICALS IN (DCPH) has a profitability rating of 2 / 10.


How financially healthy is DECIPHERA PHARMACEUTICALS IN?

The financial health rating of DECIPHERA PHARMACEUTICALS IN (DCPH) is 7 / 10.